Literature DB >> 11064354

Mechanism for bone invasion of oral cancer cells mediated by interleukin-6 in vitro and in vivo.

M Okamoto1, K Hiura, G Ohe, Y Ohba, K Terai, T Oshikawa, S Furuichi, H Nishikawa, K Moriyama, H Yoshida, M Sato.   

Abstract

BACKGROUND: Osteoclastic bone resorption is an important step in bone invasion in several malignancies. Although interleukin (IL)-6 accelerates osteoclastic bone resorption, it remains unclear whether IL-6 may be involved in bone invasion of oral cancer.
METHODS: The pit formation assay with calf femur-derived bone slices was performed to examine the bone-resorbing activity of osteoclasts and cancer cells. The chemotaxis activity of the culture media was analyzed by the use of Boyden chamber technique. Nude mice, which were inoculated with IL-6-producing oral cancer cells into masseter, were treated with anti-IL-6 neutralizing antibody, and mandibular-bone invasion of the cells was assessed.
RESULTS: BHY, a bone-invasive oral cancer cell line, but not HNT, a noninvasive cell line, produced large amounts of IL-6. In a pit formation assay, addition of conditioned medium (CM) derived from BHY but not HNT increased osteoclastic bone resorption, and the effects were inhibited by anti-IL-6 antibody. BHY-secreted IL-6 showed significant chemotaxis activity for osteoclasts. Of note, CM from the cocultivation of osteoclasts and BHY markedly enhanced the cancer cell migration, and the chemotaxis activity was significantly reduced when anti-IL-6 antibody was added into the coculture and then CM were collected, but not when the antibody was added into the CM after they were collected. Furthermore, treatment with anti-IL-6 antibody almost completely inhibited mandibular bone invasion of BHY in nude mice.
CONCLUSIONS: These results strongly suggest that IL-6 secreted by oral cancer cells plays a significant role in bone invasion. Copyright 2000 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11064354     DOI: 10.1002/1097-0142(20001101)89:9<1966::aid-cncr13>3.0.co;2-r

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Combined zoledronic acid and meloxicam reduced bone loss and tumour growth in an orthotopic mouse model of bone-invasive oral squamous cell carcinoma.

Authors:  C K Martin; W P Dirksen; M M Carlton; L G Lanigan; S P Pillai; J L Werbeck; J K Simmons; B E Hildreth; C A London; R E Toribio; T J Rosol
Journal:  Vet Comp Oncol       Date:  2013-05-08       Impact factor: 2.613

Review 2.  Galectin-3 in bone tumor microenvironment: a beacon for individual skeletal metastasis management.

Authors:  Kosei Nakajima; Dong Hyo Kho; Takashi Yanagawa; Melissa Zimel; Elisabeth Heath; Victor Hogan; Avraham Raz
Journal:  Cancer Metastasis Rev       Date:  2016-06       Impact factor: 9.264

3.  Zoledronic acid reduces bone loss and tumor growth in an orthotopic xenograft model of osteolytic oral squamous cell carcinoma.

Authors:  Chelsea K Martin; Jillian L Werbeck; Nanda K Thudi; Lisa G Lanigan; Tobie D Wolfe; Ramiro E Toribio; Thomas J Rosol
Journal:  Cancer Res       Date:  2010-10-19       Impact factor: 12.701

4.  Roles of interleukin-6 and parathyroid hormone-related peptide in osteoclast formation associated with oral cancers: significance of interleukin-6 synthesized by stromal cells in response to cancer cells.

Authors:  Kou Kayamori; Kei Sakamoto; Tomoki Nakashima; Hiroshi Takayanagi; Kei-Ichi Morita; Ken Omura; Su Tien Nguyen; Yoshio Miki; Tadahiro Iimura; Akiko Himeno; Takumi Akashi; Hisafumi Yamada-Okabe; Etsuro Ogata; Akira Yamaguchi
Journal:  Am J Pathol       Date:  2009-12-24       Impact factor: 4.307

5.  Estimation of cortisol levels in patients with premalignant disorders and oral squamous cell carcinoma.

Authors:  Priyanka Sharma; Simarpreet Virk Sandhu; Rajat Bhandari; Indu Verma; Ramanpreet Kaur Bhullar; Rajbir Kaur Khangura
Journal:  J Oral Maxillofac Pathol       Date:  2018 Jan-Apr

6.  Significance of cancer stroma for bone destruction in oral squamous cell carcinoma using different cancer stroma subtypes.

Authors:  Qiusheng Shan; Kiyofumi Takabatake; Hotaka Kawai; May Wathone Oo; Yasunori Inada; Shintaro Sukegawa; Shigeko Fushimi; Keisuke Nakano; Hitoshi Nagatsuka
Journal:  Oncol Rep       Date:  2022-02-25       Impact factor: 3.906

7.  Investigation of bone invasion and underlying mechanisms of oral cancer using a cell line-derived xenograft model.

Authors:  Qiusheng Shan; Kiyofumi Takabatake; Haruka Omori; Hotaka Kawai; May Wathone Oo; Shintaro Sukegawa; Masae Fujii; Yasunori Inada; Sho Sano; Keisuke Nakano; Hitoshi Nagatsuka
Journal:  Oncol Lett       Date:  2022-09-13       Impact factor: 3.111

8.  Skull destruction from intracranial metastasis arising from pulmonary squamous cell carcinoma: a case report.

Authors:  Imran Kader; Michael Strong; Mathew George
Journal:  J Med Case Rep       Date:  2013-01-24

9.  Gender difference in the prognostic role of interleukin 6 in oral squamous cell carcinoma.

Authors:  Chih-Jung Chen; Wen-Wei Sung; Yueh-Min Lin; Mu-Kuan Chen; Ching-Hsiao Lee; Huei Lee; Kun-Tu Yeh; Jiunn-Liang Ko
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

10.  Bone morphogenetic protein receptor 1α promotes osteolytic lesion of oral squamous cell carcinoma by SHH-dependent osteoclastogenesis.

Authors:  Qiao Qiao; Le Xu; Qingxiang Li; Yifei Wang; Han Lu; Ning Zhao; Yinfei Pu; Lin Wang; Yuxing Guo; Chuanbin Guo
Journal:  Cancer Sci       Date:  2022-03-23       Impact factor: 6.518

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.